



TO MAGNIFICO RETTORE OF UNIVERSITA' DEGLI STUDI DI MILANO

ID CODE: 4803

I the undersigned asks to participate in the public selection, for qualifications and examinations, for the awarding of a type B fellowship at **Dipartimento di Scienze della Salute**

Scientist- in - charge: **Prof.ssa Giulia Marchetti**

[Mohamad Hadla]

CURRICULUM VITAE

PERSONAL INFORMATION

Surname	Hadla
Name	Mohamad
Date of birth	[13, 04, 1987]

PRESENT OCCUPATION

Appointment	Structure
Postdoc researcher	National Tumor Institute (CRO - Aviano) Italy

EDUCATION AND TRAINING

Degree	Course of studies	University	year of achievement of the degree
PhD	Molecular and Cellular Pharmacology	Universita degli studi di Padova	2017
Master	Molecular Biology and Genetics	Universita degli studi di Pavia	2012
Bachelor	Medical Lab Technology	Jinan University of Lebanon	2010



FOREIGN LANGUAGES

Languages	level of knowledge
English	Fluent
Italian	Fluent
French	Professional
Arabic	Mother tongue

AWARDS, ACKNOWLEDGEMENTS, SCHOLARSHIPS

Year	Description of award
2017	PhD scholarship (Universita degli studi di Padova/CRO di Aviano)
2011	CARIPLLO Foundation scholarship for foreign students
2011	UNIPV fund for corporation and knowledge (Universita degli studi di Pavia)
2010	MFA fund for corporation and knowledge from the Italian Ministry of Foreign Affairs

TRAINING OR RESEARCH ACTIVITY

<p>Mammalian and murine cell culture, Cancer cell lines culture, Lentivirus preparation by transfection for cells infection, Protein extraction, Western blot, SDS-PAGE, RNA extraction, RNA analysis, Reverse Transcription PCR, Real-time PCR, Genes expression analysis, Immunofluorescence, Confocal and Epifluorescence imaging, FACS analysis, Exosomes extraction, purification, characterization and Drug loading, Bone histology, in-situ hybridisation, <i>in vivo</i> handling skills using mice models, Medical lab technology, Microbiology (Bacterial cell culture, DNA plasmid purification, biochemical detection and molecular analysis).</p> <ul style="list-style-type: none">▪ Skills in growing and characterization of 3D culture organoids models from human and mice samples, organoids culture kit development for Biofuture Medicine Inc. Italy (www.biofuturemedicine.com).▪ Liposome preparation from different substances (DLPC, DMPC, DPPC, HSPC), sizing of lipid suspension by extrusion using Avanti Mini Extruder instrument, DNA nanostructure encapsulation inside liposomes, liposomes drug remote loading, 3 stages drug delivery systems design, <i>in vitro</i> liposomes stability studies, <i>in vivo</i> Pharmacokinetics and Pharmacodynamics analyses of loaded liposomes.▪ Good command of quality control process (in lab work and research experience and advance scientific writing acquired through the trainings spent research centers in Italy and Lebanon).
--

PROJECT ACTIVITY

Year	Project
2019	Biosensors development for HPV and CML (AB Analitica and University of Verona)
2018	Development of novel kits based on exosomes and liquid biopsies
2017	Exosomes use as Drug Delivery Systems
2017	Oncogenes screening in Human Colon Cancer
2016	Synthesis of nanoparticles for drug delivery systems (Carbons, DNA origami, Silica)



Articles
Palazzolo S, Memeo L, Hadla M , Duzagac F, Steffan A, Perin T, Canzonieri V, Tuccinardi T, Caligiuri I and Rizzolio F. Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools. <i>Cancers</i> . 2020 , 12, 3165; doi:10.3390/cancers12113165
Palazzolo S, Hadla M , Russo Spena C, Caligiuri I, Rotondo R, Adeel M, Kumar V, Corona G, Canzonieri V, Toffoli G and Rizzolio F*. An Effective Multi-Stage Liposomal DNA Origami Nanosystem for In Vivo Cancer Therapy. <i>Cancers (Basel)</i> . 2019 Dec 12. PMID: 31842277
Palazzolo S, Hadla M , Russo Spena C, Bayda S, Kumar V, Lo Re F, Adeel M, Caligiuri I, Romano F, Corona G, Canzonieri V, Toffoli G and Rizzolio F*. Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin. <i>ACS Med. Chem. Lett.</i> 2019 Jan. PMID: 30996789
Hadla M* and Halabi M. A. Effect of Quorum Sensing. <i>Comprehensive Analytical Chemistry</i> . 81, 95-116, 2018 . doi.org/10.1016/bs.coac.2018.02.004. (*Corresponding author).
Bayda S, Hadla M , Palazzolo S, Corona G, Toffoli G, Rizzolio F. Inorganic Nanoparticles for Cancer Therapy: a Transition from Lab to Clinic. <i>Curr Med Chem</i> . 2018 . PMID: 29284391.
Palazzolo S*, Bayda S*, Hadla M* , Caligiuri I, Corona G, Toffoli G, Rizzolio F. The Clinical translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes. <i>Curr Med Chem</i> . 2017 Aug 29. PMID: 28875844. (*Authors equal contribution).
Bayda S, Hadla M , Palazzolo S, Kumar V, Caligiuri I, Ambrosi E, Pontoglio E, Agostini M, Tuccinardi T, Benedetti A, Riello P, Canzonieri V, Corona G, Toffoli G, Rizzolio F. Bottom-Up Synthesis of Carbon Nanoparticles with Higher Doxorubicin Efficacy. <i>Journal of Controlled Release</i> . 2017 Feb 28;248:144-152. PMID:28093297.
Hadla M , Palazzolo S, Corona G, Caligiuri I, Canzonieri V, Toffoli G, Rizzolio F. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. <i>Nanomedicine (Lond)</i> . 2016 Sep; 11(18):2431-41. PMID:27558906.
Kumar V, Bayda S, Hadla M , Caligiuri I, Russo Spena C, Palazzolo S, Kempter S, Corona G, Toffoli G, Rizzolio F. Enhanced Chemotherapeutic Behavior of Open-Caged DNA@Doxorubicin Nanostructures for Cancer Cells. <i>J Cell Physiol</i> . 2016 Jan; 231(1):106-10. PMID: 26031628.
Toffoli G, Hadla M , Corona G, Caligiuri I, Palazzolo S, Semeraro S, Gamini A, Canzonieri V, Rizzolio F. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. <i>Nanomedicine (Lond)</i> . 2015 Oct; 10(19):2963-71. PMID: 26420143.
Sponchia G, Ambrosi E, Rizzolio F, Hadla M , Del Tedesco A, Russo Spena C, Toffoli G, Riello P, Benedetti A. Biocompatible tailored zirconia mesoporous nanoparticles with high surface area for theranostic applications. <i>J. Mater. Chem. B</i> , 2015 , 3, 7300-7306. DOI: 10.1039/C5TB01424G.



Declarations given in the present curriculum must be considered released according to art. 46 and 47 of DPR n. 445/2000.

The present curriculum does not contain confidential and legal information according to art. 4, paragraph 1, points d) and e) of D.Lgs. 30.06.2003 n. 196.

Place and date: Padova, 9/12/2020

SIGNATURE

IRHARTVA) UADLA